NEW HAVEN, Conn., Feb. 27, 2020 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the U.S. Food and Drug Administration (FDA) has approved Nurtec ODT (rimegepant) for the acute treatment of migraine in…Original Article
You may also like
Dupixent (dupilumab) Approved in the U.S. as the First...
U.S. Food and Drug Administration Updates Camzyos...
FDA Grants Isturisa (osilodrostat) Expanded Indication...
Neurelis Announces FDA Approval for Immediate Use...
Mirum’s Livmarli Now FDA Approved in Tablet...
FDA Grants Interchangeable Designation to Yuflyma...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.